¼¼°èÀÇ ±ÙÀ° ¼Ò¸ð¼º Áúȯ ½ÃÀå º¸°í¼­(2025³â)
Muscle Wasting Disorders Global Market Report 2025
»óǰÄÚµå : 1825468
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,457,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,334,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,211,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

±ÙÀ° ¼Ò¸ð¼º Áúȯ ½ÃÀåÀÇ ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2029³â¿¡´Â CAGR 14.0%·Î 295¾ï 2,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø±â°£ÀÇ ¼ºÀåÀº ±ÔÁ¦ Áö¿ø, ȯÀÚ Áö¿ø ÀÌ´Ï¼ÅÆ¼ºê, ÇコÄɾî ÀÎÇÁ¶ó °³¹ß, ÀÓ»ó½ÃÇèÀÇ ¼¼°èÈ­, ¸ÂÃãÀÇ·á Á¢±Ù¿¡ ±âÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¿ø°ÝÀÇ·á µµÀÔ, Áø´ÜÀÇ ±â¼úÀû Áøº¸, Á¦Ç°ÀÇ Çõ½Å, °øµ¿¿¬±¸ Á¦ÈÞ, Ä¡·áÁ¦ÀÇ Áøº¸, ºÐÀÚ ¸ÞÄ¿´ÏÁòÀÇ Á¶»ç, ¹ÙÀÌ¿ÀÀǾàǰÀÇ Çõ½Å µîÀÌ ÀÖ½À´Ï´Ù.

ÇâÈÄ 5³â°£ÀÇ ¿¹Ãø ¼ºÀå·ü 14.0%´Â °ú°Å ¿¹Ãø¿¡¼­ 0.2% ¼ÒÆø °¨¼ÒÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀå¼¼ µÐÈ­´Â ÁÖ·Î ¹Ì±¹°ú ´Ù¸¥ ±¹°¡ °£ÀÇ °ü¼¼ÀÇ ¿µÇâ ¶§¹®ÀÔ´Ï´Ù. °ü¼¼ »ó½ÂÀº ½ºÀ§½º³ª ÀϺ»¿¡¼­ Á¶´ÞÇÏ´Â ¹Ì¿À½ºÅ¸Æ¾ ¾ïÁ¦Á¦¿Í Àü±âÀÚ±ØÀåÄ¡ÀÇ ºñ¿ëÀ» Àλó½ÃÄÑ È¯ÀÚÀÇ ±â´É ÀúÇϸ¦ ¾ÇÈ­½Ã۰í Èñ¼ÒÁúȯÀÇ Ä¡·áºñ¸¦ »ó½Â½Ã۱⠶§¹®¿¡ ¹Ì±¹ÀÇ ½Å°æ±Ù Ŭ¸®´Ð¿¡ ºÎ´ãÀ» ÁÙ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ¶ÇÇÑ »óÈ£°ü¼¼¿Í ¹«¿ªÀÇ ±äÀå°ú ÇѰè Áõ°¡·Î ÀÎÇÑ ¼¼°è °æÁ¦¿Í ¹«¿ª¿¡ ´ëÇÑ ¾Ç¿µÇâÀ¸·Î ÀÎÇØ ±× ¿µÇâÀÌ ´õ¿í ±¤¹üÀ§ÇØÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾É±â ½¬¿î »ýȰ½À°üÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ±â ¶§¹®¿¡ ±ÙÀ° ¼Ò¸ð¼º Áúȯ ½ÃÀåÀÇ ÇâÈÄ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. Á¦ÇÑµÈ ½Åü Ȱµ¿°ú ÃÖ¼ÒÇÑÀÇ ¿îµ¿À¸·Î Ư¡Áö¾îÁö´Â ¶óÀÌÇÁ½ºÅ¸ÀÏÀº ±ÙÀ° ±â´É¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâ°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ±× °á°ú ±Ù·Â°ú Áö±¸·ÂÀÌ ÀúÇÏµÇ¾î ±ÙÀ° ¼Ò¸ð¼º ÁúȯÀÇ ¿øÀÎÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. 2022³â ¼¼°èº¸°Ç±â±¸(WHO)´Â û¼Ò³âÀÇ 80% ÀÌ»ó, ¼ºÀÎÀÇ 27%°¡ ±ÇÀåµÇ´Â ½ÅüȰµ¿ ¼öÁØÀ» ÃæÁ·ÇÏÁö ¸øÇß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¾É±â ½¬¿î ¶óÀÌÇÁ½ºÅ¸ÀÏ¿¡ ´ëÇÑ µ¿ÇâÀº ±ÙÀ° ¼Ò¸ð¼º Áúȯ ½ÃÀåÀÇ È®´ë¸¦ ÃßÁøÇÏ´Â Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

CSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Muscle wasting disorders, also known as muscle atrophy or muscle wasting, encompass a range of conditions marked by the gradual reduction of muscle mass and strength. This phenomenon can be attributed to various factors, such as lack of use, aging, malnutrition, neurodegenerative diseases, and specific medical conditions.

Primary treatments for muscle wasting disorders include medications, physical therapy, nutritional therapy, surgery, gene therapy, and various other interventions. Medications for muscle wasting disorders are specifically designed to address conditions such as sarcopenia, cachexia, and muscular dystrophy. The goal of these medications is to enhance muscle mass and improve overall muscle function. They find application in the treatment of conditions such as muscular dystrophy, amyotrophic lateral sclerosis (ALS), and others, being utilized by hospitals, rehabilitation centers, specialty clinics, and other end-users.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The muscle wasting disorders market research report is one of a series of new reports from The Business Research Company that provides muscle wasting disorders market statistics, including muscle wasting disorders industry global market size, regional shares, competitors with a muscle wasting disorders market share, detailed muscle wasting disorders market segments, market trends and opportunities, and any further data you may need to thrive in the muscle wasting disorders industry. This muscle wasting disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The muscle wasting disorders market size has grown rapidly in recent years. It will grow from $15.06 billion in 2024 to $17.49 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increasing aging population, rising incidence of chronic diseases, advancements in research and development, increased awareness of early diagnosis, emerging therapeutic approaches.

The muscle wasting disorders market size is expected to see rapid growth in the next few years. It will grow to $29.52 billion in 2029 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to regulatory support, patient advocacy initiatives, healthcare infrastructure development, globalization of clinical trials, personalized medicine approaches. Major trends in the forecast period include telemedicine adoption, technological advancements in diagnostics, product innovation, collaborations and partnerships, advancements in therapeutics, research on molecular mechanisms, biopharmaceutical innovation.

The forecast of 14.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. neuromuscular clinics by driving up the cost of myostatin inhibitors and electrical stimulation devices sourced from Switzerland and Japan, exacerbating functional decline in patients and raising rare disease care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in adherence to a sedentary lifestyle is poised to drive the growth of the muscle wasting disorders market in the future. A sedentary lifestyle, characterized by limited physical activity and minimal exercise, has been linked to negative impacts on muscle function. This can result in a reduction in muscle strength and endurance, contributing to muscle wasting disorders. In 2022, the World Health Organization reported that over 80% of adolescents and 27% of adults did not meet recommended physical activity levels. This trend towards a sedentary lifestyle is a significant factor propelling the expansion of the muscle wasting disorders market.

Key players in the muscle wasting disorders market are actively developing innovative products, particularly novel gene therapies, to better address the needs of patients with muscle wasting disorders. Novel gene therapy involves manipulating gene expression or altering the biological properties of living cells to achieve therapeutic effects. For example, Sarepta Therapeutics, a US-based biotechnology company, introduced Elevidys in June 2023. Elevidys, the first gene therapy approved by the U.S. FDA for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 to 5, utilizes recombinant gene therapy to deliver a gene leading to a shortened protein with selected domains of the dystrophin protein. The therapy is administered as a single intravenous infusion.

In September 2023, Biogen Inc., a US-based biotechnology company, acquired Reata Pharmaceuticals Inc. for $7.3 billion. This acquisition is expected to enhance Biogen's rare disease portfolio, specifically addressing Friedreich's ataxia - a genetic, progressive, and debilitating neuromuscular disorder affecting the nervous system and muscles. Reata Pharmaceuticals Inc., the acquired US-based pharmaceutical company, focuses on developing therapeutics for neuromuscular disorders and muscle wasting disorders, further solidifying Biogen's position in the market.

Major companies operating in the muscle wasting disorders market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Roche Holding AG, Novartis AG, Sanofi, GlaxoSmithKline (GSK), Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Acceleron Pharma Inc., Biogen Inc., Santhera Pharmaceuticals Holding AG, Mitsubishi Tanabe Pharma, Nippon Shinyaku Co. Ltd. (NS Pharma, Inc.), Sarepta Therapeutics Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Axogen, Inc., FibroGen Inc., Cytokinetics Incorporated, Italfarmaco S.p.A., Scholar Rock, Bellerophon Therapeutics, Akashi Therapeutics, aTyr Pharma, Metabolic Solutions Development Company, Synaptogenix, MyoKardia, Inc., MyoTherix Inc.

North America was the largest region in the muscle wasting disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle wasting disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the muscle wasting disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The muscle wasting disorders market consists of revenues earned by entities by providing services such as diagnostic services, medical services, support services and community services. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle wasting disorders market also includes sales of anabolic steroids, growth hormone, enobosarm and bimagrumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Muscle Wasting Disorders Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on muscle wasting disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for muscle wasting disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The muscle wasting disorders market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Muscle Wasting Disorders Market Characteristics

3. Muscle Wasting Disorders Market Trends And Strategies

4. Muscle Wasting Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Muscle Wasting Disorders Growth Analysis And Strategic Analysis Framework

6. Muscle Wasting Disorders Market Segmentation

7. Muscle Wasting Disorders Market Regional And Country Analysis

8. Asia-Pacific Muscle Wasting Disorders Market

9. China Muscle Wasting Disorders Market

10. India Muscle Wasting Disorders Market

11. Japan Muscle Wasting Disorders Market

12. Australia Muscle Wasting Disorders Market

13. Indonesia Muscle Wasting Disorders Market

14. South Korea Muscle Wasting Disorders Market

15. Western Europe Muscle Wasting Disorders Market

16. UK Muscle Wasting Disorders Market

17. Germany Muscle Wasting Disorders Market

18. France Muscle Wasting Disorders Market

19. Italy Muscle Wasting Disorders Market

20. Spain Muscle Wasting Disorders Market

21. Eastern Europe Muscle Wasting Disorders Market

22. Russia Muscle Wasting Disorders Market

23. North America Muscle Wasting Disorders Market

24. USA Muscle Wasting Disorders Market

25. Canada Muscle Wasting Disorders Market

26. South America Muscle Wasting Disorders Market

27. Brazil Muscle Wasting Disorders Market

28. Middle East Muscle Wasting Disorders Market

29. Africa Muscle Wasting Disorders Market

30. Muscle Wasting Disorders Market Competitive Landscape And Company Profiles

31. Muscle Wasting Disorders Market Other Major And Innovative Companies

32. Global Muscle Wasting Disorders Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Muscle Wasting Disorders Market

34. Recent Developments In The Muscle Wasting Disorders Market

35. Muscle Wasting Disorders Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â